Evidence map›Paper›PMID 40945027›Full record

ArticleNeurobiology of aging2025

Cognitive resilience in preclinical Alzheimer's disease: Higher NPTX2 and VGF levels are associated with reduced cognitive decline.

Claire L Anderson, Alden L Gross, Corinne Pettigrew, Juan P Vazquez, Abhay Moghekar, Sungtaek Oh, Chan Hyun Na, Marilyn Albert, Paul Worley, Anja Soldan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurobiology of aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Claire L AndersonDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: cande148@jh.edu.
Alden L GrossDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Corinne PettigrewDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Juan P VazquezDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Abhay MoghekarDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sungtaek OhDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Chan Hyun NaDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Marilyn AlbertDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Paul WorleyDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Anja SoldanDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
BIOCARD Research Team

Funding

Project 2 MeasurementU19AG033655 · NIA · JOHNS HOPKINS UNIVERSITY · PI Abhay Moghekar · 2014 to 2026
$51.5M
Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI Corinne Pettigrew · 2020 to 2026
$29.3M
Biomarkers of Cognitive Decline among Normal Individuals: The BIOCARD cohortU01AG033655 · NIA · JOHNS HOPKINS UNIVERSITY · PI ALBERT, MARILYN S. · 2009 to 2013
$11.2M
NIA NIH HHS P30 AG066507NIA NIH HHS U01 AG033655NIA NIH HHS U19 AG033655
6 · The paper itself

Abstract

Prior work suggests higher levels of the synaptic proteins neuronal pentraxin 2 (NPTX2) and neurosecretory protein VGF (VGF) may confer cognitive resilience to Alzheimer's disease (AD) pathology. Little is known about how these measures relate to long-term cognitive trajectories among individuals initially cognitively unimpaired. This study examined how rates of cognitive decline (mean follow-up=16 years) among 269 initially cognitively unimpaired individuals from the BIOCARD study (M baseline age=57.7 years, 59 % female) are associated with baseline levels of three synaptic proteins measured in cerebrospinal fluid (CSF), using parallel reaction monitoring mass spectrometry: VGF, NPTX2, and the associated AMPA glutamate receptor subunit 4 (GluA4). Baseline CSF biomarker levels of AD pathology (e.g., Aβ

Indexed as

Alzheimer DiseaseCognitionCognitive DysfunctionC-Reactive ProteinNerve Tissue ProteinsAgedAmyloid beta-PeptidesBiomarkersFemaleFollow-Up StudiesHumansMaleMiddle AgedPentraxinsPeptide FragmentsReceptors, AMPAAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersC-Reactive Proteinglutamate receptor ionotropic, AMPA 4Nerve Tissue ProteinsPentraxinsPeptide FragmentsReceptors, AMPAtau ProteinsCognitionCognitive resilienceCSF biomarkersEpisodic memoryExecutive functionPreclinical Alzheimer’s disease

Identifiers

PMID40945027
PMCPMC12687933

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.